Effects of ketone bodies on kidney function and blood pressure
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity in Patients with Essential Hypertension
This study is testing if taking ketone bodies can help improve kidney function and lower blood pressure in people with high blood pressure.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 19 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gødstrup Hospital Academic / other |
| Locations | 1 site (Herning) |
| Trial ID | NCT06418074 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of exogenous ketosis on renal function, renal perfusion, and sodium excretory capacity in patients with essential hypertension. Nineteen participants will be randomly assigned to receive either ketone bodies or a placebo for five days, followed by a washout period and a crossover to the alternative treatment. Key measurements will include glomerular filtration rate and renal blood flow, assessed using advanced imaging techniques. The study aims to elucidate the therapeutic potential of ketone bodies in managing hypertension and kidney health.
Who should consider this trial
Good fit: Ideal candidates are adults with essential hypertension who are on a maximum of two antihypertensive medications and meet specific renal function criteria.
Not a fit: Patients with diabetes, heart failure, or those on a ketogenic diet may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatment options for managing hypertension and improving kidney function.
How similar studies have performed: While the effects of ketosis on renal function are being explored, this specific approach is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Essential hypertension (treatment with maximum 2 antihypertensive drugs) * eGFR \> 60ml/min * BMI \< 35 kg/m2 * Urine Albumin Creatinin Ratio (UACR) \< 300mg/g * Safe contraception if women in childbearing age Exclusion Criteria: * Diabetes type 1 or 2 * Heart Failure * Pregnancy or breast feeding * Liver disease * Malignant disease * Recent acute myocardial infarction (AMI), apoplexia/transient ischemic attack (TIA) (within 12 months of inclusion) * Daily use of prescription drugs (expect for contraceptives) * Alcohol or drug abuse * Periodic fasting * Routinely intake of ketogenic diet * Treatment with immunosuppressants or SGLT2-inhibitors
Where this trial is running
Herning
- The University Clinic in Nephrology and Hypertension, Gødstrup Region Hospital — Herning, Denmark (Recruiting)
Study contacts
- Principal investigator: Trine Z Lyksholm, MD — The University Clinic for Nephrology and Hypertenion, Regional Hospital Godstrup
- Study coordinator: Trine Z Lykshom, MD
- Email: trizur@rm.dk
- Phone: 78432534
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.